First post here on HotCopper as I was a quiet reader over the last few years...
I totally agree Vivo. Efti will be a blockbuster and big Pharma won't let that slip through their fingers. Especially Merck with Keytruda patent expiring 2028 and the chance to extend it. I was working for one big Pharma player and there is nothing worse than a drug becoming generic. Just look at Pfizer selling their generic drug business 2019. Sales dropped tremendously. I don't think Merck will let that happen to Keytruda.
What is the timeline for AIPAC and TACTI-003 in 2022?
Overnight Market report, page-106
-
- There are more pages in this discussion • 2,674 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |